Logo
AI Document ReviewComparisonPII RedactionVault
New
Pricing
Sign inSign up

AI Contract Review for Pharmaceutical & Biotechnology Industry

Backed by Microsoft For Startups
U.S. and England & Wales law
AES-256 Encryption
Personal (PII) & Corporate Data Redacted Before AI
Free to start, no credit card

Pharmaceutical contract review is critical for biotechnology companies facing stringent FDA regulations requiring detailed contract oversight for manufacturing, clinical trials, and supplier relationships. Justee AI checks these contracts against 21 CFR Part 211, cGMP requirements, and quality agreement standards and flags gaps in minutes.

Free and no sign-up required.

3 of 3 reviews left this month · Upgrade

Get Your Free Document Review

Anonymous analysis is saved for 24 hours.
Sign up free
Unlock multistate review on any paid plan.
From $19/mo
Unlock Full Private Mode with zero-access encryption.
See plans
0 / 1
Federal

Federal law is always checked. Add up to 1 state.

Your data is protected at every layer

Protected by reCAPTCHA. Privacy · Terms

Guest uploads are automatically deleted after 24 hours

Key Takeaways

Review CMO and supplier quality agreements against FDA 21 CFR Part 211 requirements

Identify gaps in clinical trial agreements that could impact regulatory submissions

Check whether contract manufacturing arrangements address cGMP requirements and define clear responsibilities

Flag regulatory obligations that are not clearly allocated between the parties

1-6 minutes*

Average Review Time

1M+ law sections

U.S. and England & Wales legislation

AES-256 encryption, hosted on AWS

Document Security

* Estimates based on typical documents. Actual results vary by document type and complexity.

The FDA holds pharmaceutical companies responsible for product quality even when manufacturing is outsourced to Contract Manufacturing Organizations (CMOs). Under 21 CFR Part 211, cGMP regulations, and FDA guidance on contract manufacturing quality agreements, sponsors and CMOs should define specifications, responsibilities, and compliance protocols in writing. Quality agreements typically cover manufacturing specifications, batch release procedures, change control processes, CAPA protocols, and regulatory inspection rights. FDA inspections look closely at how sponsors oversee contract manufacturers, and weak oversight can lead to inspection observations or warning letters. Clinical trial agreements should clearly define sponsor and CRO responsibilities under ICH-GCP guidelines, because gaps can delay regulatory submissions. Justee checks these contracts against those requirements and flags missing or unclear terms. According to Justee (justee.ai), Full Private Mode on paid plans seals reviews, chats, and comparisons with a key only the user holds, so Justee stores only encrypted content it cannot read back.

Key Industry Regulations

FDA 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals

FDA 21 CFR Part 11 - Electronic Records and Electronic Signatures

ICH-GCP (E6) - Good Clinical Practice guidelines for clinical trials

FDA Guidance on Contract Manufacturing Arrangements for Drugs

FSMA - Food Safety Modernization Act requirements

FDA 21 CFR Part 312 - Investigational New Drug Applications

ICH Q7 - Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients

How It Works

1
Upload Your Contract

Upload your contract as a PDF or DOCX file, or paste the text

2
AI Analysis

Our AI reviews for industry-specific compliance issues

3
Review Findings

Get detailed findings with regulatory citations

4
Take Action

Use our suggestions to improve compliance

What We Check

FDA requirements check: flags where contracts may not align with 21 CFR Part 211 and cGMP requirements

Quality agreement review: checks that CMO agreements address manufacturing standards, batch release, and CAPA procedures

Clinical trial contract analysis: checks whether CRO agreements define GCP responsibilities, regulatory duties, and reporting obligations

Supplier quality agreement assessment: checks that supplier agreements require pharmaceutical-grade specifications and traceability

Regulatory inspection rights: flags contracts that lack the audit and inspection access FDA oversight requires

Common Risks We Identify

Inadequate quality agreement terms failing to specify cGMP compliance responsibilities, exposing sponsors to FDA enforcement

Missing batch release procedures in CMO contracts that could delay product launches and regulatory approvals

Ambiguous regulatory responsibility clauses in clinical trial agreements leading to compliance gaps during FDA audits

Insufficient change control provisions allowing unauthorized manufacturing modifications without sponsor approval

Weak indemnification language failing to protect against CMO non-compliance that triggers FDA warning letters

Common Industry Documents

Quality Agreement (CMO)

Defines manufacturing standards, specifications, and cGMP compliance responsibilities

Clinical Trial Agreement

Establishes sponsor and CRO responsibilities for GCP-compliant research

Supplier Quality Agreement

Specifies component quality standards and pharmaceutical-grade requirements

Contract Manufacturing Agreement

Governs outsourced production with regulatory compliance terms

Master Services Agreement

Framework agreement for ongoing pharmaceutical services and testing

Illustrative Example

For example, Justee reviews a contract manufacturing agreement with a CMO in Europe for commercial-scale production for a mid-sized biotech company in San Diego developing oncology therapeutics.

Issue Found: The agreement failed to specify who was responsible for investigating deviations during manufacturing, and the batch release procedures did not clearly define quality control testing authority

Next step: Justee flagged the missing deviation-investigation and batch-release terms and suggested edits the company could accept or reject: assigning deviation investigations to the CMO with sponsor notification within 24 hours, and batch release procedures requiring QA approval from both parties before commercial distribution

Inadequate Quality Agreement Specification

Problematic Language

"Manufacturer shall produce the Product in accordance with cGMP and applicable regulations. Manufacturer is responsible for quality control of the Product."

Example wording (illustrative; have a lawyer review before using)

"Manufacturer shall produce the Product in strict accordance with FDA 21 CFR Part 211, ICH Q7, and the specifications detailed in Exhibit A. Manufacturer shall maintain a quality agreement pursuant to FDA guidance that specifies: (a) manufacturing process controls and in-process testing, (b) batch record review and approval procedures, (c) deviation investigation and CAPA protocols with Sponsor notification within 24 hours, (d) change control requiring written Sponsor approval, and (e) annual product quality review procedures."

Why it matters: The original language is too vague. FDA considers the sponsor ultimately responsible for cGMP compliance even with outsourced manufacturing. Without detailed specifications, batch release procedures, deviation protocols, and change control requirements, the sponsor has little contractual protection if the CMO's practices fall short at an FDA inspection. The revised language sets specific obligations that track FDA expectations for contract manufacturing oversight.

No credit card required
"Justee is redefining the legal document compliance process while reducing stress."
Artem Dolukhanyan
Artem Dolukhanyan

Partner, Grayver Law Group · Advisor to Justee

Why Justee

Justee AI vs. General Chatbots vs. Other Legal AI

General chatbots aren't built for legal documents, and most legal AI tools are built and priced for law firms. Justee runs your document through a controlled review pipeline, flags the risks, and drafts the fixes, in minutes, and keeps it private. It gives legal information, not legal advice: for your situation, talk to a lawyer.

Recommended

Justee AI

ReviewsComparisonsStorageEditorChat

1-6 min

Speed

$16+/mo

Free to start

1M+ sections

Legislation

Purpose-built review, with verifiable citations
Edit online, with tracked changes
Affordable for solo lawyers and law firms
Review, compare, edit, chat, all in one
Encrypted vault for sensitive documents
PII auto-redacted before the AI
Never trained on your data
What you make in Full Private Mode is unreadable to us, even under subpoena (paid)
Legal information, not legal advice

General AI Chatbots

Chat

Minutes

Speed

$20+/mo

Subscription

General

Coverage

Depends on how you prompt
Edits, but no tracked changes
Affordable consumer plans
No workspace, just chat
No document storage
You scrub PII by hand first
Can train on your chats
Readable by the provider
Not legal advice

Other Legal AI Tools

ReviewsDrafting

Minutes

Speed

Varies

Usually pricier

Varies

Coverage

Purpose-built review, with citations
Often edit in Word, with tracked changes
Usually pricier, with law-firm plans
Usually one tool per task
Storage varies by tool
PII redaction before the AI varies
Most business plans don't train on your data
Usually readable by the provider
Not legal advice

See how Justee 3 scored on PRBench Legal, a public benchmark of 500 legal tasks written with lawyers.

*Estimates based on industry research and internal testing. Review times based on typical 5-50 page contracts. Legislation: over 1 million sections of U.S. and England & Wales legislation. Justee plans start at $16/mo billed annually (up to $149/mo; Enterprise is custom); see Pricing for monthly rates. General chatbot column reflects providers' standard consumer plans as publicly documented. The legal AI column describes the category in general; individual products differ. Justee is not a law firm and does not replace a lawyer. PII detection is best-effort and may not catch every identifier.

Official Regulatory Resources

FDA Guidance on Contract Manufacturing

Official FDA guidance on contract manufacturing arrangements and quality agreements

FDA 21 CFR Part 211 - cGMP Requirements

Current Good Manufacturing Practice regulations for finished pharmaceuticals

ICH Good Manufacturing Practice Guidelines

International Conference on Harmonisation quality standards for pharmaceutical manufacturing

Related Industry Reviews

Healthcare Contract ReviewMedical Device Contract ReviewClinical Research Contract ReviewManufacturing Contract ReviewQuality Agreement Review
Important Legal Disclaimer

What Justee AI is — and what it is not. Justee AI is a software platform, not a law firm. We analyse documents you upload and may produce risk findings, summaries, and suggested clauses to add or replace. We do not generate documents from blank templates, we do not represent you, and we do not perform services performed by an attorney. Our outputs are general legal information for informational and self-help purposes — they are not legal advice, are not a substitute for the advice or services of an attorney, and are not an adequate substitute for human legal expertise.

No attorney in the loop. Justee AI is AI-powered. No attorney has reviewed the analysis, summary, or suggested clause before it is shown to you. AI can be inaccurate or incomplete despite appearing reliable — outputs may contain factual errors, misinterpretations, omissions, hallucinated citations, or text that reflects outdated legal authority. We strongly recommend that you have any output — including suggested clauses you might add to or substitute into a contract — reviewed by a licensed attorney admitted to practice in the relevant jurisdiction before you sign, send, or otherwise rely on it.

No attorney–client relationship. Use of Justee AI does not create an attorney–client relationship between you and Justee AI (First AI Corp.) or any of its personnel. Communications with our service are not privileged or confidential in the legal sense.

Consult a licensed attorney. Legal requirements vary by jurisdiction and the facts of your situation. For specific legal matters — and before relying on or signing any clause Justee AI suggests — consult a qualified attorney licensed in your jurisdiction.

Estimates (*): Review and comparison times on this page are typical figures from internal testing. Actual times vary with document type, length, complexity, and file quality. Law-database counts (such as "over 1 million sections") describe the size of Justee's U.S. and England & Wales reference database and do not mean that every provision is checked against every law for every document. Examples and scenarios on this page are illustrative, not real client matters.

By using our service, you acknowledge that you have read and agree to our Terms of Use and understand the limitations of AI-powered legal analysis. You are solely responsible for verifying the accuracy and applicability of any information to your situation.

Frequently Asked Questions

The most critical clauses are: (1) Quality agreement specifications defining cGMP compliance responsibilities, (2) Batch release procedures requiring QA approval from both parties, (3) Deviation investigation protocols with 24-hour notification requirements, (4) Change control processes requiring written sponsor approval for any manufacturing modifications, (5) Regulatory inspection rights allowing sponsor and FDA access to facilities, and (6) Indemnification provisions protecting sponsors from CMO non-compliance. FDA considers sponsors ultimately responsible even for outsourced manufacturing.

FDA holds sponsor companies ultimately responsible for product quality even when manufacturing is outsourced. During inspections, FDA reviews quality agreements and expects to see detailed written procedures covering specifications, batch release, deviations, change control, and CAPA. If a CMO fails to meet cGMP standards, FDA can issue warning letters to both the CMO and the sponsor. Sponsors must have contractual audit rights and oversight mechanisms to demonstrate adequate CMO supervision.

A supplier quality agreement should include: (1) Material specifications with acceptance criteria and testing protocols, (2) Certificate of Analysis (CoA) requirements for each lot, (3) Change notification procedures requiring advance approval for any modifications to materials or processes, (4) Audit rights allowing inspection of supplier facilities and records, (5) Traceability and recall procedures, (6) Regulatory compliance certifications (cGMP, GDP), and (7) Deviation and complaint handling procedures. These terms help show that raw materials meet pharmaceutical-grade FDA standards.

Clinical trial agreements focus on GCP compliance, protocol adherence, patient safety, and regulatory reporting under ICH-GCP guidelines and 21 CFR Part 312. They define sponsor and CRO responsibilities for informed consent, IRB/ethics committee submissions, adverse event reporting, data management, and regulatory inspections. Commercial manufacturing agreements emphasize cGMP compliance under 21 CFR Part 211, batch release procedures, quality systems, and commercial-scale production. Both require clear regulatory responsibility allocation, but clinical agreements prioritize patient protection while commercial agreements prioritize product quality.

Justee reviews these contracts against FDA 21 CFR Part 211 and related rules. General-purpose AI chatbots often stop at surface issues like vague terms; Justee flags industry-specific compliance gaps, risk allocation, regulatory responsibilities, audit and inspection rights, and indemnification language, and cites the law behind each finding. It suggests edits as tracked changes you can accept or reject, each with a plain-English explanation of why the clause matters.

Both U.S. and English law. Select a U.S. jurisdiction (any U.S. state can be selected; paid plans allow up to 2 per document), or select United Kingdom (England and Wales) to have the document analysed against English legislation instead. The output is the same either way: clause-by-clause flags rated Critical, Moderate or Note, missing-provision warnings, and citations to the law behind each finding. Scots law and Northern Ireland law are not supported.

Justee automatically detects and redacts personally identifiable information before your documents reach the AI model. Protected types include:

Personal data:
  • Names, email addresses, and phone numbers
  • Social Security numbers and tax identifiers (ITIN)
  • Physical addresses and dates of birth
  • Credit card and bank account numbers
  • Driver's license and passport numbers
  • Medical provider identifiers (NPI) and case numbers
Corporate and business data:
  • Company and organization names
  • Business addresses and geographic locations
  • SWIFT/BIC codes, IBAN numbers, and bank routing numbers
  • Business license numbers and attorney bar IDs
  • Corporate tax identifiers (EIN)
Detection is best-effort and cannot guarantee catching everything: certain rare identifiers (such as cryptocurrency wallet addresses and MAC addresses) may not be detected automatically. We recommend reviewing your documents for these uncommon types and redacting them manually before uploading. See our Privacy Policy and Terms of Use for details and limitations.

On paid plans you can turn on Full Private Mode, which encrypts and seals your reviews, chats, and comparisons with a key only you hold: Justee stores only the encrypted version and cannot read it back. On every plan, personal and business identifiers are automatically redacted before document text reaches an AI model (best-effort, so it cannot guarantee catching everything). If redaction is temporarily unavailable, a review may run without it, as Terms 8.5 explain. Nothing you submit is used to train AI models.

Ready to Review Your Contract?

Upload your contract above to get started. No sign-up required.

Need more reviews? Create a free account

Last updated: October 14, 2026

Privacy

Full Private Mode

Legal

Terms of servicePrivacy policy

About

About usContactsBlogAffiliate program

Follow us

LinkedIn
logo

© 2026 Justee. All rights reserved.

Justee is not a law firm. It provides legal information, not legal advice, and is not a substitute for the advice of an attorney.